NIH Grants $470 Million for Study of Long COVID

The study aims to recruit 40,000 adults and children to get a better sense of the condition that can last weeks or months after infection.

Written byLisa Winter
| 2 min read
Man sitting on bed with his head in his hands

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, TZIDO

After becoming infected with SARS-CoV-2, the majority of people recover in a couple of weeks. For a significant number of patients, though, symptoms can hang on for more than four months, a condition known as long COVID. The National Institutes of Health (NIH) announced yesterday (September 15) that it has awarded a $470 million grant to the REsearching COVID to Enhance Recovery (RECOVER) Initiative to study 40,000 people for more insights into the mechanisms behind the condition, along with possible treatments.

In June, the NIH announced the creation of the RECOVER Initiative to study how and why some people with past SARS-CoV-2 infections experience symptoms such as fatigue, loss of taste and/or smell, coughing, and mental fog for months on end. RECOVER now boasts more than 100 researchers from more than 30 institutions, and close to half a billion dollars in funding.

“We know some people ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies